PLRX Stock Forecast: Pliant Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Pliant Therapeutics, Inc. is $2. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 68 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Pliant Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (89): The share count has been shrinking and the company is not leaning on new borrowing.
Momentum (15): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
PLRX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PLRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Mar 2026 | Canaccord Genuity | Maintains | Hold | $4.00 → $3.00 |
| 12 Mar 2026 | Piper Sandler | Maintains | Overweight | $4.00 → $3.00 |
| 7 Nov 2025 | RBC Capital | Maintains | Sector Perform | — |
| 10 Oct 2025 | JP Morgan | Downgrade | Underweight | — |
| 8 Aug 2025 | Piper Sandler | Maintains | Overweight | — |
| 18 Mar 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 4 Mar 2025 | Cantor Fitzgerald | Reinstates | Neutral | — |
| 4 Mar 2025 | Citigroup | Maintains | Neutral | — |
| 4 Mar 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 4 Mar 2025 | Needham | Downgrade | Hold | — |
| 4 Mar 2025 | RBC Capital | Maintains | Sector Perform | — |
| 4 Mar 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 3 Mar 2025 | Leerink Partners | Downgrade | Market Perform | — |
| 14 Feb 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 14 Feb 2025 | Needham | Reiterates | Buy | — |
| 10 Feb 2025 | Canaccord Genuity | Downgrade | Hold | — |
| 10 Feb 2025 | Citigroup | Downgrade | Neutral | — |
| 10 Feb 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 10 Feb 2025 | JP Morgan | Downgrade | Neutral | — |
| 10 Feb 2025 | Needham | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for PLRX.
This page is one stock. Monday covers all of them.
PLRX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
PLRX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Pliant Therapeutics, Inc. returned −61.9% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
PLRX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.2×
- EV / EBITDA
- —
Cheaper than 94% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −50.3%
- Return on assets
- −23.3%
- Dividend yield
- —
Higher than 22% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Pliant Therapeutics, Inc. has a market value of $36.9M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$92.3M.
Diluted earnings per share, trailing twelve months: −$1.49.
Free cash flow in the twelve months to 30 June 2026: −$70.9M.
Pliant Therapeutics, Inc. employs 49 people.
Data provided by Twelve Data
PLRX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at PLRX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Pliant Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about PLRX
What is the PLRX stock price forecast for 2026-2027?
The median 12-month analyst price target for Pliant Therapeutics, Inc. is $2. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is PLRX stock a buy right now?
Of the 4 analysts covering Pliant Therapeutics, Inc., 0 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Pliant Therapeutics, Inc. 68 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank PLRX?
As at 21 Nov 2026, Pliant Therapeutics, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Issuance (89 of 100).
Will PLRX stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts is $2, and Ticker Nerd's factor model ranks Pliant Therapeutics, Inc. 68 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the PLRX stock forecast for 2030?
No analyst covering Pliant Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $2 over the next 12 months.
How has PLRX stock performed over the past year?
Pliant Therapeutics, Inc. returned -61.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Pliant Therapeutics, Inc. do?
Pliant Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapies for fibrotic diseases and related conditions. The company’s current pipeline centers on oral and other targeted drug candidates designed to modulate key pathways involved in fibrosis, with programs being studied in areas such as idiopathic pulmonary fibrosis, primary sclerosing cholangitis, liver fibrosis, solid tumors, and muscular dystrophies.
About Pliant Therapeutics, Inc.
Pliant Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapies for fibrotic diseases and related conditions. The company’s current pipeline centers on oral and other targeted drug candidates designed to modulate key pathways involved in fibrosis, with programs being studied in areas such as idiopathic pulmonary fibrosis, primary sclerosing cholangitis, liver fibrosis, solid tumors, and muscular dystrophies. Its research platform is built around integrin biology, which plays an important role in cell signaling, tissue remodeling, and disease progression. Pliant Therapeutics Inc. operates as a specialist developer within the biotechnology sector, contributing to the broader market for treatments aimed at serious, chronic, and often underserved diseases.
CEO Dr. Bernard Jozef Coulie M.B.A., M.D., Ph.D. · 49 employees · United States · https://pliantrx.com